Protagonist Therapeutics (PTGX) Revenue (2017 - 2026)
Protagonist Therapeutics (PTGX) posted Revenue of $56.4 million for Q1 2026, up 657.94% sequentially from $7.4 million in Q4 2025, and up 99.03% YoY from $28.3 million in Q1 2025.
Protagonist Therapeutics (PTGX) Revenue (2017 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Revenue for 10 years, with the latest figure at $56.4 million in Q1 2026.
- Quarterly Revenue rose 99.03% year-over-year to $56.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.1 million (down 63.36% YoY) and the FY2025 annual result came in at $46.0 million, down 89.41% from the prior year.
- Revenue improved to $56.4 million in Q1 2026 per PTGX's latest filing, from $7.4 million in the prior quarter.
- Over five years, Revenue peaked at $255.0 million in Q1 2024 and troughed at $859000.0 in Q2 2022.
- A 5-year average of $50.6 million and a median of $16.6 million in 2022 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2025: Revenue surged 315.61% in 2022, then tumbled 95.49% in 2025.
- Over 5 years, Revenue stood at $859000.0 in 2022, then surged by 5720.72% to $50.0 million in 2023, then soared by 230.0% to $165.0 million in 2024, then sank by 95.49% to $7.4 million in 2025, then soared by 657.94% to $56.4 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $56.4 million, $7.4 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 213.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 213.48 Mn |
| Mar 31, 2026 | 56.37 Mn |
| Dec 31, 2025 | 7.44 Mn |
| Sep 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | 5.55 Mn |
| Mar 31, 2025 | 28.32 Mn |
| Dec 31, 2024 | 165.00 Mn |
| Sep 30, 2024 | 4.68 Mn |
| Jun 30, 2024 | 4.17 Mn |
| Mar 31, 2024 | 254.95 Mn |
| Dec 31, 2023 | 50.00 Mn |
| Jun 30, 2022 | 859,000.00 |
| Mar 31, 2022 | 25.72 Mn |
| Dec 31, 2021 | 8.62 Mn |
| Sep 30, 2021 | 10.29 Mn |
| Jun 30, 2021 | 2.27 Mn |
| Mar 31, 2021 | 6.19 Mn |
| Dec 31, 2020 | 5.65 Mn |
| Sep 30, 2020 | 13.11 Mn |
| Jun 30, 2020 | 6.22 Mn |